| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H15Br2N3O4 |
| Molecular Weight | 545.18 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(Br)C=C(C=C1Br)C2=NOC(=N2)C(=O)NCC3=CC=C(OC4=CC=CC=C4)C=C3
InChI
InChIKey=DSFNLJXHXBIKDS-UHFFFAOYSA-N
InChI=1S/C22H15Br2N3O4/c23-17-10-14(11-18(24)19(17)28)20-26-22(31-27-20)21(29)25-12-13-6-8-16(9-7-13)30-15-4-2-1-3-5-15/h1-11,28H,12H2,(H,25,29)
| Molecular Formula | C22H15Br2N3O4 |
| Molecular Weight | 545.18 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
IOWH032 is a synthetic extracellular CFTR inhibitor, originally developed to treat diarrhea, that entered Phase II clinical trials in 2013 but did not progress further in clinical development. iOWH032 has low CFTR inhibition potency (IC50 > 5 uM) and hence rapid (seconds or less) dissociation from CFTR. iOWH032 inhibited secretion by nearly 70% as measured on a semi-quantitative fecal output scale.
